Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
The mainstay of therapy for [[vitamin D]] deficiency is [[vitamin D]], either vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol).
The mainstay of therapy for [[vitamin D]] deficiency is [[vitamin D]], either vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol). Vitamin D supplements could be used as a daily loading regimen followed by the maintenance. The alternative regimen is high weekly dose (stoss therapy) and maintenance therapy.  


==Medical therapy==
==Medical therapy==

Revision as of 03:33, 1 September 2017

Vitamin D deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Vitamin D deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines for Management

Case Studies

Case #1

Sandbox: sadaf On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox: sadaf

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox: sadaf

CDC on Sandbox: sadaf

Sandbox: sadaf in the news

Blogs on Sandbox: sadaf

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Sandbox: sadaf

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

The mainstay of therapy for vitamin D deficiency is vitamin D, either vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol). Vitamin D supplements could be used as a daily loading regimen followed by the maintenance. The alternative regimen is high weekly dose (stoss therapy) and maintenance therapy.

Medical therapy

There are two major forms of vitamin D; ergocalciferol (vitamin D2), cholecalciferol (vitamin D3). A systematic review and meta-analysis of Tripkovic L et al. in 2011, indicated that vitamin D3 compared to vitamin D2 is more effective to raise the serum level of 25OHD and is preferred for treatment and prevention. [1]

  • Endocrine Society published a clinical practice guideline for the treatment of vitamin D deficiency to reach and sustain a serum 25(OH)D level of 30 ng/ml.[2]
Age Loading dose Alternative dose Maintenance dose
0-1 y 2000 IU/d orally for 6 weeks 50,000 IU/w orally for 6 weeks 400-1000 IU/d
1-18 y 2000 IU/d orally for 6 weeks 50,000 IU/w orally for 6 weeks 600-1000 IU/d
Adults 50,000 IU/w orally for 8 weeks 6000 IU/d orally for 6 weeks 1500–2000 IU/d
Nursing home residents 50,000 IU/three times per week for 1 month 100,000 IU of vitamin D every 4 months
High risk patients* 6000-10,000 IU/d 3000–6000 IU/d

High risk patients include African American, obese, patients with malabsorption syndromes and who are on anticonvulsants.

  • The American Academy of Pediatrics (AAP) recommends an initial phase of treatment with high dose of vitamin D for 2-3 months to treat vitamin D deficiency rickets. The recommended dose is 1000 IU/d in neonates, 1000-5000 IU/d in infants, and 5000 IU/d for children over 1-year-old. [3] After raising the serum 25 OHD levels to 30 ng/ml, a maintenance dose of 400 IU/d is required for all age groups. Higher maintenance dose (800 IU/d) might be needed in at risk groups. [4]
  • An alternative strategy for treatment, also known as stoss therapy, is a single dose therapy in patients over 1-month-old. 100,000 – 600,000 IU of ergocalciferol orally single dose followed by maintenance therapy is recommended, especially in noncompliant patients. [5]

Special circumstances

  • Patients on anticonvulsant drugs are at risk of vitamin D deficiency. If osteopenia occurs, treatment with 2000-4000 IU/d must be started. In case of osteomalacia, a larger dose of vitamin D, 5000-15000 IU/d is required. [6]

References

  1. Tripkovic, L.; Lambert, H.; Hart, K.; Smith, C. P.; Bucca, G.; Penson, S.; Chope, G.; Hypponen, E.; Berry, J.; Vieth, R.; Lanham-New, S. (2012). "Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis". American Journal of Clinical Nutrition. 95 (6): 1357–1364. doi:10.3945/ajcn.111.031070. ISSN 0002-9165.
  2. Holick, Michael F.; Binkley, Neil C.; Bischoff-Ferrari, Heike A.; Gordon, Catherine M.; Hanley, David A.; Heaney, Robert P.; Murad, M. Hassan; Weaver, Connie M. (2011). "Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline". The Journal of Clinical Endocrinology & Metabolism. 96 (7): 1911–1930. doi:10.1210/jc.2011-0385. ISSN 0021-972X.
  3. Lee, Ji Yeon; So, Tsz-Yin; Thackray, Jennifer (2013). "A Review on Vitamin D Deficiency Treatment in Pediatric Patients". The Journal of Pediatric Pharmacology and Therapeutics. 18 (4): 277–291. doi:10.5863/1551-6776-18.4.277. ISSN 1551-6776.
  4. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008). "Vitamin D deficiency in children and its management: review of current knowledge and recommendations". Pediatrics. 122 (2): 398–417. doi:10.1542/peds.2007-1894. PMID 18676559.
  5. Shah BR, Finberg L (1994). "Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method". J. Pediatr. 125 (3): 487–90. PMID 8071764.
  6. Drezner MK (2004). "Treatment of anticonvulsant drug-induced bone disease". Epilepsy Behav. 5 Suppl 2: S41–7. doi:10.1016/j.yebeh.2003.11.028. PMID 15123011.


Template:WikiDoc Sources